ORMP - Oramed Pharmaceuticals Inc

https://www.oramed.com

Momentum: Bearish

Recent News

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

Business Insider • 4 months, 2 weeks ago • score: 0.24

JERUSALEM, April 28, 2025 ( GLOBE NEWSWIRE ) -- Alpha Tau Medical Ltd. ( "Alpha Tau", or the "Company" ) ( NASDAQ: DRTS, DRTSW ) , the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that it has successfully closed a registered direct offering ( the ...

Bullish

Congressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals Stock - Oramed Pharmaceuticals ( NASDAQ:ORMP )

Benzinga • 6 months, 2 weeks ago • score: 0.27

A February filing shows that Representative Brad Knott reported a sale in Oramed Pharmaceuticals ORMP, valued between $15,001 and $50,000. The transaction date is listed as February 25, 2025, with the report published on February 25, 2025. At present, Oramed Pharmaceuticals shares are trading ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for the administration of polypeptides. The company is headquartered in New York, New York.

52W High

$3.09

52W Low

$1.82

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.68

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.52

EV/Revenue (<3 favorable)

2.87

P/S (TTM) (<3 favorable)

45.72

P/B (<3 favorable)

0.59

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

13.16%

Institutions (25–75% balanced)

17.78%

Shares Outstanding

41,003,600

Float

32,556,900

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

2,000,000

Gross Profit (TTM)

13,000

EPS (TTM)

-0.61

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-6.84%

ROE (TTM) (>15% strong)

-0.15%

EPS YoY (Quarterly) (>10% good)

0.41

Revenue YoY (Quarterly) (>8% good)

-1.00

Momentum

Bearish momentum

Value

0.0813

0.0723

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025